BioHarvest grants new long-term equity incentives

BioHarvest Sciences Inc. reported that its board approved new long‑term incentive awards for employees, officers and directors under its equity incentive plan.

Rhea-AI Filing Summary

BioHarvest Sciences Inc. reported that its board approved new long‑term incentive awards for employees, officers and directors under its equity incentive plan. The package includes 516,812 stock options and 264,121 restricted share units, all granted at the March 13, 2026 closing share price.

The options have a 10‑year term, and both options and RSUs vest quarterly over three years starting March 13, 2026. The company highlights that equity‑based compensation is intended to align personnel with shareholder interests while preserving cash, supporting its strategy in botanical synthesis, nutraceutical products and CDMO services.

Insights

Equity compensation and governance analyst

Routine equity grants align staff incentives with shareholders using non‑cash compensation.

BioHarvest Sciences granted 516,812 stock options and 264,121 RSUs under its equity plan, with a 10‑year option term and three‑year quarterly vesting from March 13, 2026. This structure rewards long‑term retention and performance rather than short‑term results.

The company emphasizes that equity awards help conserve cash while tying compensation to future shareholder value. Actual dilution impact depends on outstanding share count and future vesting, which are not detailed here. Overall, the update reflects standard incentive practices without signaling a major strategic shift.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What long-term incentive awards did BioHarvest Sciences (BHST) grant in March 2026?

BioHarvest Sciences granted 516,812 stock options and 264,121 restricted share units as long-term incentives. These equity awards target employees, officers and directors, aligning compensation with shareholder value while supporting retention across the company’s core business segments.

How do BioHarvest Sciences’ new stock options and RSUs vest?

Both the stock options and RSUs vest quarterly over three years starting March 13, 2026. This staggered vesting schedule encourages ongoing retention and performance, as recipients earn their equity progressively instead of receiving it all at once.

What is the term and pricing basis of BioHarvest Sciences’ new stock options?

The granted stock options are valid for 10 years from March 13, 2026 and are priced at that day’s closing share value. This links potential upside directly to long-term share price performance over the coming decade.

Why is BioHarvest Sciences using equity-based incentives instead of higher cash pay?

The company states that equity-based incentives help reward and retain talent while maintaining disciplined cash management. By paying partly in stock options and RSUs, BioHarvest reduces immediate cash outflows and ties compensation to long-term shareholder value creation.

Which groups at BioHarvest Sciences are receiving the new long-term incentives?

The long-term incentive awards are being granted to employees, officers and directors. Management explains that this broad participation is meant to align the entire team—scientific, operational and leadership personnel—with the company’s long-term growth and shareholder return objectives.

How do the new incentives relate to BioHarvest Sciences’ Botanical Synthesis strategy?

The company links the equity awards to its strategy of expanding its patented Botanical Synthesis platform in nutraceutical products and CDMO services. It believes attracting and retaining top scientific, operational and commercial talent is essential to executing this growth plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/16/2026 - 02:11 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission file number: 001-42389

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SUBMITTED HEREWITH

Exhibits:

Exhibit	Description
99.1	News Release dated March 13, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOHARVEST SCIENCES INC.
	(Registrant)
Date: March 13, 2026	/s/ David Ryan
	Name: David Ryan
	Title: Vice-President, Investor Relations & Secretary

BioHarvest Sciences Announces Grant of Long-Term Incentive Awards to Employees, Officers and Directors

Vancouver, British Columbia and Rehovot, Israel – March 13, 2026 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (NASDAQ: BHST), a company pioneering its patented Botanical Synthesis technology platform, today announced that its Board of Directors has approved the grant of long‑term incentive (“LTI”) awards to employees, officers and directors under the Company’s equity incentive plan. These grants are designed to align the interests of the Company’s team with those of shareholders while supporting BioHarvest’s continued growth and innovation across its core business segments.

The awards consist of a combination of stock options and restricted share units (“RSUs”) totaling 516,812 stock options and 264,121 RSUs. All stock options will be valid for 10 years as of today, and both stock options and RSUs will be priced at today’s closing share value and will vest quarterly for a three-year period starting March 13, 2026.

“Equity‑based incentives play a central role in aligning our team with long‑term shareholder value creation,” said Zaki Rakib, Chairman of BioHarvest Sciences. “BioHarvest’s achievements are driven by the extraordinary talent and commitment of our employees, scientists and leadership team. These long‑term incentives ensure that the people building the Company participate directly in the value they help create for shareholders.”

Importantly, the use of equity‑based incentives allows the Company to reward and retain top talent while maintaining a disciplined approach to cash management. By utilizing stock options and RSUs as part of its compensation structure, BioHarvest minimizes the immediate cash impact on the Company while ensuring that compensation remains closely linked to long‑term value creation for shareholders.

BioHarvest continues to execute on its long‑term strategy of expanding its proprietary Botanical Synthesis platform across both consumer nutraceutical products and its CDMO division, leveraging the Company’s unique ability to produce plant‑derived compounds at commercial scale. The Company believes that attracting and retaining exceptional scientific, operational and commercial talent remains one of the most important drivers of sustainable growth and shareholder return.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance that equity incentives will result in long term retention of key personnel as matters such as competitive opportunities, personal life issues and other external factors beyond the control of the company may result in personnel turnover. While the company believes that aligning the interests of key personnel with shareholders will support Company growth and value, this cannot be assured as external factors such as general economic trends, inflation, trade restrictions, regulatory approval delays and changes in consumer preferences may influence growth and changes in Company value.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

BioHarvest Corporate Contact:

Dave Ryan

(604) 622-1186

info@bioharvest.com

Investor Relations Contact:

Chuck Padala, Managing Director

LifeSci Advisors

chuck@lifesciadvisors.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 NEWS RELEASE DATED MARCH 13, 2026 8.5 KB